Intellia Therapeutics, Inc.
NTLA- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652130
In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 329 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Intellia Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 284
- +5 vs. Q2 2025
- Shares held
- 104.2M
- +4.73M (+4.8%) vs. Q2 2025
- Total value
- $1.80B
- +$866.1M (+92.8%) vs. Q2 2025
- New holders
- 43
- 104 more added
- Sold out
- 38
- 78 more reduced
4 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NTLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 329 | $2.43B |
| Q1 2026 | 306 | $1.41B |
| Q4 2025 | 295 | $938.9M |
| Q3 2025 | 284 | $1.80B |
| Q2 2025 | 283 | $933.8M |
| Q1 2025 | 296 | $720.3M |
| Q4 2024 | 295 | $1.16B |
| Q3 2024 | 284 | $1.92B |
| Q2 2024 | 291 | $2.02B |
| Q1 2024 | 284 | $2.51B |
| Q4 2023 | 293 | $2.60B |
| Q3 2023 | 286 | $2.53B |
| Q2 2023 | 292 | $3.19B |
| Q1 2023 | 291 | $2.93B |
| Q4 2022 | 304 | $2.72B |
| Q3 2022 | 321 | $3.81B |
| Q2 2022 | 301 | $3.44B |
| Q1 2022 | 348 | $4.71B |
| Q4 2021 | 372 | $7.60B |
| Q3 2021 | 366 | $8.34B |
| Q2 2021 | 337 | $10.0B |
| Q1 2021 | 261 | $5.07B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Intellia Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Corton Capital Inc. | 0 | $0 | 0.00% | −27,137−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −23,600−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −17,649−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −16,268−100.0% | Sold out |
| Inceptionr LLC | 0 | $0 | 0.00% | −16,210−100.0% | Sold out |
| Mariner, LLC | 0 | $0 | 0.00% | −14,507−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −14,457−100.0% | Sold out |
| DnB Asset Management AS | 0 | $0 | 0.00% | −13,586−100.0% | Sold out |
| Independent Financial Group, LLC | 0 | $0 | 0.00% | −12,559−100.0% | Sold out |
| CIBC World Markets Inc. | 0 | $0 | 0.00% | −11,478−100.0% | Sold out |
| Green Alpha Advisors, LLC | 0 | $0 | 0.00% | −11,007−100.0% | Sold out |
| Sigma Planning Corp | 0 | $0 | 0.00% | −10,616−100.0% | Sold out |
| Colony Group, LLC | 0 | $0 | 0.00% | −10,088−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −7,673−100.0% | Sold out |
| PEAK6 LLC | 0 | $0 | 0.00% | −7,601−100.0% | Sold out |
| Raiffeisen Bank International AG | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Resona Asset Management Co.,Ltd. | 0 | $0 | 0.00% | −900−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −237−100.0% | Sold out |
| WealthTrak Capital Management LLC | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| Itau Unibanco Holding S.A. | 0 | $0 | 0.00% | −53−100.0% | Sold out |
| Mid-American Wealth Advisory Group, Inc. | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| South State Corp. | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| First Horizon Advisors, Inc. | – | – | – | – | Not filed |